Silence Therapeutics Plc

SLN

Latest QuantConomy context for SLN: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for SLN. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for SLN

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
ownership passive increase	slightly bullish	65	Jul 9, 02:16 AM	Richard Griffiths increased passive stake in SLN from 4.20% to 21.70% - (13G - passive investment) - 30,844,458 shares - [moderate slightly bullish signal]
corporate event reg fd disclosure	neutral	70	Jun 23, 08:40 PM	SLN filed 8-K: Regulation FD Disclosure - 1 material event - [strong neutral signal]
earnings earnings release	neutral	40	Mar 5, 12:00 AM	SLN filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-05. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

OWNERSHIP signals are experimental: historical 13D/G coverage is still being backfilled, so results may be sparse or empty.

Market	Exchange	Source	Asset record
SLN	NASDAQ	alpaca	Silence Therapeutics Plc American Depository Share
SLN	NASDAQ	alphavantage	Silence Therapeutics Plc
SLN	NASDAQ	fmp	Silence Therapeutics plc

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Jun 29, 2026	Griffiths Richard Ian	Insider	sale	330,072	—	—	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.